60 related articles for article (PubMed ID: 17688945)
21. Alternative splicing of c-fos pre-mRNA: contribution of the rates of synthesis and degradation to the copy number of each transcript isoform and detection of a truncated c-Fos immunoreactive species.
Jurado J; Fuentes-Almagro CA; Prieto-Alamo MJ; Pueyo C
BMC Mol Biol; 2007 Sep; 8():83. PubMed ID: 17888145
[TBL] [Abstract][Full Text] [Related]
22. Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Amirzargar AA; Razavi SM; Sharifian RA; Rabbani H; Shokri F
Hum Immunol; 2008 Oct; 69(10):666-74. PubMed ID: 18722491
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis.
Martinelli S; Maffei R; Castelli I; Santachiara R; Zucchini P; Fontana M; Bonacorsi G; Leonardi G; Marasca R; Torelli G
Leuk Res; 2008 Apr; 32(4):593-7. PubMed ID: 17928052
[TBL] [Abstract][Full Text] [Related]
24. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
25. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia.
Eisele L; Prinz R; Klein-Hitpass L; Nückel H; Lowinski K; Thomale J; Moeller LC; Dührsen U; Dürig J
Eur J Haematol; 2009 Oct; 83(4):320-7. PubMed ID: 19500131
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes.
Plass C; Byrd JC; Raval A; Tanner SM; de la Chapelle A
Br J Haematol; 2007 Dec; 139(5):744-52. PubMed ID: 17961188
[TBL] [Abstract][Full Text] [Related]
27. A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies.
Newcomb EW; el Rouby S; Thomas A
Mol Carcinog; 1995 Dec; 14(4):227-32. PubMed ID: 8519411
[TBL] [Abstract][Full Text] [Related]
28. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.
el Rouby S; Thomas A; Costin D; Rosenberg CR; Potmesil M; Silber R; Newcomb EW
Blood; 1993 Dec; 82(11):3452-9. PubMed ID: 8241511
[TBL] [Abstract][Full Text] [Related]
29. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction.
Mous R; Jaspers A; Luijks DM; Mellink CH; van Oers MH; Kater AP; Eldering E
Leukemia; 2009 Jul; 23(7):1352-5. PubMed ID: 19340003
[No Abstract] [Full Text] [Related]
30. [Mutations in genes involved in splicing in human malignancies].
Damm F; Nguyen-Khac F; Kosmider O; Fontenay M; Bernard OA
Med Sci (Paris); 2012 May; 28(5):449-53. PubMed ID: 22642991
[No Abstract] [Full Text] [Related]
31. Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrant p53 expression.
Aguilar-Santelises M; Magnusson KP; Wiman KG; Mellstedt H; Jondal M
Int J Cancer; 1994 Aug; 58(4):474-9. PubMed ID: 8056442
[TBL] [Abstract][Full Text] [Related]
32. Global Shift in Alternative Splicing and Therapeutic Susceptibilities in Leukemia Driven by METTL3 Overexpression.
Janin M; Esteller M
Blood Cancer Discov; 2023 May; 4(3):176-179. PubMed ID: 37067902
[TBL] [Abstract][Full Text] [Related]
33. A novel high-sensitivity diagnostic test for B-CLL.
Expert Rev Mol Diagn; 2006 Sep; 6(5):643-5. PubMed ID: 17009899
[No Abstract] [Full Text] [Related]
34. Explaining the biological activity of transactivation-deficient p53 variants.
Tang M; Wahl GM; Nistér M
Nat Genet; 2006 Apr; 38(4):395-6; author reply 396-7. PubMed ID: 16570054
[No Abstract] [Full Text] [Related]
35. Evaluation of Caspase-9b and PP2Acα2 as potential biomarkers for chronic lymphocytic leukemia.
Domínguez-Berrocal L; Zhang X; Zini JM; Fominaya J; Rebollo A; Bravo J
Biomark Res; 2016; 4():9. PubMed ID: 27152197
[TBL] [Abstract][Full Text] [Related]
36. Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al.
Weinberg JB; Brander DM; Christensen DJ; Friedman DR
Br J Haematol; 2019 Aug; 186(4):637. PubMed ID: 31044417
[No Abstract] [Full Text] [Related]
37. Functional assessment of p53 in chronic lymphocytic leukemia.
Le Garff-Tavernier M; Blons H; Nguyen-Khac F; Pannetier M; Brissard M; Gueguen S; Jacob F; Ysebaert L; Susin SA; Merle-Béral H
Blood Cancer J; 2011 Feb; 1(2):e5. PubMed ID: 22829111
[No Abstract] [Full Text] [Related]
38. Genetics: Splicing the pieces of the chronic lymphocytic leukemia puzzle.
Villanueva MT
Nat Rev Clin Oncol; 2012 Jan; 9(2):66. PubMed ID: 22249443
[No Abstract] [Full Text] [Related]
39. Genetics: p53 variant increases cancer risk.
Seton-Rogers S
Nat Rev Cancer; 2016 Apr; 16(5):273. PubMed ID: 27112206
[No Abstract] [Full Text] [Related]
40. Increased Δ133p53 mRNA in lung carcinoma corresponds with reduction of p21 expression.
Fragou A; Tzimagiorgis G; Karageorgopoulos C; Barbetakis N; Lazopoulos A; Papaioannou M; Haitoglou C; Kouidou S
Mol Med Rep; 2017 Apr; 15(4):1455-1460. PubMed ID: 28260096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
